This inhibition of mitogenic signaling pathways in prostate carcinoma leads to alteration of cell cycle regulators, inhibition of growth and androgen-independent prostate carcinoma cells loss and expression of insulin-like growth factor-binding protein 3 (1). This evidence concerns the gene IGFBP3 and prostate carcinoma.